Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 13/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | HINT1 | P49773 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23138150 | 1.00 | TYMP (0.45) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL30866953 | 0.95 | TYMP (0.44) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL17861001 | 0.95 | TYMP (0.44) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL6519372 | 0.95 | TYMP (0.44) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL12964677 | 0.94 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL12803763 | 0.94 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL12803769 | 0.94 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL7066599 | 0.94 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL668541 | 0.94 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL16707296 | 0.94 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117756871-A | Method for preparing N-acetylgalactosamine oligonucleotide conjugate based on click chemistry technology | 常州合全药业有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-117756873-A | Method for preparing N-acetylgalactosamine oligonucleotide conjugate based on click chemistry technology | 常州合全药业有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-117756872-A | Method for preparing N-acetylgalactosamine oligonucleotide conjugate based on click chemistry technology | 常州合全药业有限公司 | 2024-03-26 | — | — | CN | claimed |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | ELI LILLY AND CO (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260083854-A1 | CONJUGATES COMPRISING BIS-MSPT LINKER | LILLY CO ELI (US) | 2026-03-26 | — | — | US | disclosed |
| US-20250381284-A1 | PRNP RNAi AGENTS | LILLY CO ELI (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250249118-A1 | SARM1 RNAi AGENTS | ELI LILLY AND COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-20250188472-A1 | SARM1 RNA INTERFERENCE AGENTS | ELI LILLY AND COMPANY | 2025-06-12 | — | — | US | disclosed |
| WO-2025108237-A1 | LIPID COMPOUND, NUCLEIC ACID CONJUGATE AND USE THEREOF | 施能康生物科技有限公司 | 2025-05-30 | — | — | WO | disclosed |
| CN-120025369-A | Lipid compound, nucleic acid conjugate and application thereof | 施能康生物科技有限公司 | 2025-05-23 | — | — | CN | disclosed |
| WO-2025075868-A1 | PPP1R15B RNA INTERFERENCE AGENTS | ELI LILLY AND COMPANY (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20060223770-A1 | IRNA agents targeting VEGF | ALNYLAM EUROPE AG (DE) | 2006-10-05 | — | — | US | disclosed |
| US-20060217330-A1 | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs | BANK OF AMERICA, N.A. | 2006-09-28 | — | — | US | disclosed |
| US-20060094032-A1 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | disclosed |
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | SIRNA THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-6686463-B2 | FEWER SYNTHETIC STEPS; INVOLVES FORMATION OF A 5',4'-BRIDGING SILYL PROTECTING GROUP TO FORM A FUSED SILOXANE ON THE FURAN RING | SIRNA THERAPEUTICS, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1313752-A2 | METHODS FOR SYNTHESIZING NUCLEOSIDES, NUCLEOSIDE DERIVATIVES AND NON-NUCLEOSIDE DERIVATIVES | RIBOZYME PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002018405-A2 | METHODS FOR SYNTHESIZING NUCLEOSIDES, NUCLEOSIDE DERIVATIVES AND NON-NUCLEOSIDE DERIVATIVES | RIBOZYME PHARMACEUTICALS, INCORPORATED (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094032-A1 | iRNA agents targeting VEGF | KDR, FLT4, SNRPE | TYMP 1464/4885KDM4E 3027/4885TAS1R3 3615/4885 |
| US-20250188472-A1 | SARM1 RNA INTERFERENCE AGENTS | SARNP, SARM1, SMN1; SMN2 | TYMP 3968/4885KDM4E 3641/4885TAS1R3 2542/4885 |
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | TYMP 16/4885KDM4E 1810/4885TAS1R3 3530/4885 |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | TYMP 17/4885KDM4E 1814/4885TAS1R3 3980/4885 |
| US-20260083854-A1 | CONJUGATES COMPRISING BIS-MSPT LINKER | TFRC, TNFSF11, FTH1 | TYMP 2336/4885KDM4E 1111/4885TAS1R3 3510/4885 |
| US-20060223770-A1 | IRNA agents targeting VEGF | KDR, FLT4, SNRPE | TYMP 1464/4885KDM4E 3027/4885TAS1R3 3615/4885 |
| US-20250381284-A1 | PRNP RNAi AGENTS | PRNP, SARNP, PCNP | TYMP 2294/4885KDM4E 3584/4885TAS1R3 3005/4885 |
| US-20250249118-A1 | SARM1 RNAi AGENTS | SARNP, SARM1, SMN1; SMN2 | TYMP 3243/4885KDM4E 2821/4885TAS1R3 2868/4885 |
| US-20260139257-A1 | PLIN1 RNAi INTERFERENCE AGENTS | PLIN1, PLIN3, PLIN5 | TYMP 3637/4885KDM4E 815/4885TAS1R3 4066/4885 |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | TYMP 14/4885KDM4E 1689/4885TAS1R3 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.